Aabakken L, Osnes M, Frenzel W
Department of Gastroenterology, Ullevål Hospital, Oslo, Norway.
Aliment Pharmacol Ther. 1996 Apr;10(2):151-6. doi: 10.1046/j.1365-2036.1996.719899000.x.
Gastrointestinal effects are common adverse effects associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Lornoxicam is a new nonsteroidal anti-inflammatory drug and its gastroduodenal tolerability was compared to that of naproxen in a randomized, double-blind, crossover study.
Eighteen healthy male volunteers received lornoxicam 8 mg b.d. or naproxen 500 mg b.d. administered orally over two 7-day dosing periods. Upper endoscopy was performed by two independent investigators at the beginning and end of each dosing regimen.
Lornoxicam 8 mg b.d. caused significantly less mucosal injury than naproxen 500 mg b.d. in the stomach/duodenal bulb, as well as in the mid/distal duodenum.
These findings may have favourable implications for lornoxicam in the clinical setting, if this dose provides optimal control of arthritic pain.
胃肠道不良反应是与非甾体抗炎药（NSAIDs）相关的常见副作用。氯诺昔康是一种新型非甾体抗炎药，在一项随机、双盲、交叉研究中，对其胃十二指肠耐受性与萘普生进行了比较。
18名健康男性志愿者在两个为期7天的给药期内，每日两次口服8毫克氯诺昔康或每日两次口服500毫克萘普生。在每个给药方案开始和结束时，由两名独立研究人员进行上消化道内镜检查。
每日两次服用8毫克氯诺昔康在胃/十二指肠球部以及十二指肠中/远端造成的黏膜损伤明显少于每日两次服用500毫克萘普生。
如果该剂量能最佳控制关节炎疼痛，这些发现可能对氯诺昔康在临床应用中具有有利影响。
